Incyte Corporation (LON:0J9P)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 13.30B |
| Revenue (ttm) | 3.58B |
| Net Income (ttm) | 884.23M |
| Shares Out | n/a |
| EPS (ttm) | 4.39 |
| PE Ratio | 15.04 |
| Forward PE | 10.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 741 |
| Average Volume | 1,901 |
| Open | 92.00 |
| Previous Close | 92.47 |
| Day's Range | 88.83 - 94.28 |
| 52-Week Range | 53.61 - 95.50 |
| Beta | 0.74 |
| RSI | 61.95 |
| Earnings Date | Oct 28, 2025 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial numbers in USD Financial StatementsNews
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)---- $INCY--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System.
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ISAD2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis.
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show ...
Incyte: Strong Growth, Margin Expansion, And Low Valuation
Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and poten...
Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript
Incyte Corporation (NASDAQ:INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer October 19, 2025 1:30 PM EDT Company Particip...
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO25--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC.
Notable Thursday Option Activity: PYPL, HPE, INCY
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in PayPal Holdings Inc (Symbol: PYPL), where a total of 118,410 contracts have traded so far, repre...
3 Biotech Stocks I Am Accumulating
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
Seeking Alpha's healthcare quant picks ahead of Q3 earnings: McKesson, Incyte top-rated stocks
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12.12% in the S&P 500 index, rise 3.18% so far this year, compared to 13.14% r...
Incyte (INCY) Announces Promising Study Results for Cancer Treatments
Incyte (INCY) Announces Promising Study Results for Cancer Treatments
Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2025--Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the ESMO Congress 2025.
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Rating | INCY Stock News
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Rating | INCY Stock News
Incyte to Report Third Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2...
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Incyte Corporation (INCY) Appoints New Principal Financial Officer
Incyte Corporation (INCY) Appoints New Principal Financial Officer
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
INCY and ABBV lead S&P 500 healthcare gainers in Q3; MOH and ALGN lag
INCY vs. ARGX: Which Stock Is the Better Value Option?
INCY vs. ARGX: Which Stock Is the Better Value Option?
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pha...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Cramer reveals 5 undervalued stocks that are must-own heading into 2026
Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025. “Sometimes, it can feel like...
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | INCY Stock News
RBC Capital Raises Price Target for Incyte (INCY) to USD 81 | INCY Stock News
Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher
Even as the indexes soar to new heights, CNBC's Jim Cramer said investors can still find relatively inexpensive names. "Sometimes it can feel like there's nothing left to buy," he said.
Stifel Raises Price Target for Incyte (INCY) to $115 While Maintaining Buy Rating | INCY Stock News
Stifel Raises Price Target for Incyte (INCY) to $115 While Maintaining Buy Rating | INCY Stock News